Prestige Consumer Healthcare Inc. income statement

In fiscal 2026, Prestige Consumer Healthcare Inc. reported revenue of $1.09bn, down 4.3% on the year before, operating income of $309m (a 28.4% margin) and net income of $190m, or $3.91 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Prestige Consumer Healthcare Inc.: income statement, annual
Fiscal year	2010Mar 2010	2011Mar 2011	2012Mar 2012	2013Mar 2013	2014Mar 2014	2015Mar 2015	2016Mar 2016	2017Mar 2017	2018Mar 2018	2019Mar 2019	2020Mar 2020	2021Mar 2021	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026	LTMJun 2026
Revenue	293	337	441	617	596	713	806	882	1,041	976	963	943	1,087	1,128	1,125	1,138	1,089	1,105
Cost of revenue	—	—	—	—	—	—	339	382	465	420	411	396	466	502	501	503	493	513
Gross profit	153	171	227	344	336	406	467	500	577	556	552	547	621	625	624	634	596	591
General and administrative	34	42	57	51	48	81	72	89	85	90	89	83	107	107	106	108	116	131
Operating income	78	76	103	192	189	208	260	206	215	68	291	297	330	−22	342	337	309	290
Interest expense	23	27	41	84	69	81	85	94	106	105	96	82	64	4	5	2	—	—
Net interest income	—	—	—	—	—	—	—	—	—	—	—	—	−64	−69	−67	−48	−42	—
Provision for credit losses	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0	0	10	—
Income before tax	53	49	61	106	102	127	157	111	107	−38	191	204	262	−94	276	284	257	—
Income tax	21	19	24	41	29	49	57	41	−232	−2	49	39	57	−12	67	70	67	62
Net income	32	29	37	66	73	78	100	69	340	−36	142	165	205	−82	209	215	190	172
Diluted EPS	$0.64	$0.58	$0.73	$1.27	$1.39	$1.49	$1.88	$1.30	$6.34	−$0.69	$2.78	$3.25	$4.04	−$1.65	$4.17	$4.29	$3.91	$3.57
Diluted shares (average)	50m	50m	51m	51m	52m	53m	53m	53m	54m	52m	51m	51m	51m	50m	50m	50m	49m	48m
EBITDA	90	86	114	205	202	225	284	231	249	99	320	328	362	10	373	367	341	323

US$ millions unless shown otherwise. Fiscal quarters.

Prestige Consumer Healthcare Inc.: income statement, quarterly
Quarter	2025 Q2Sept 2024	2025 Q3Dec 2024	2025 Q4Mar 2025	2026 Q1Jun 2025	2026 Q2Sept 2025	2026 Q3Dec 2025	2026 Q4Mar 2026	2027 Q1Jun 2026
Revenue	284	290	297	250	274	283	282	266
Cost of revenue	126	129	127	109	123	126	135	130
Gross profit	157	161	170	140	152	157	146	136
General and administrative	26	26	27	28	28	30	30	43
Operating income	84	92	88	72	80	82	75	53
Interest expense	12	11	−35	—	—	—	—	—
Net interest income	−12	−11	−11	−10	−10	−11	−11	—
Provision for credit losses	—	—	0	—	—	—	0	—
Income tax	17	19	24	14	27	15	11	9
Net income	54	61	50	47	42	47	54	29
Diluted EPS	$1.09	$1.22	$1.01	$0.95	$0.86	$0.97	$1.13	$0.61
EBITDA	92	99	96	79	87	90	84	61

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: PBH vs TRLV ANIP vs PBH HRMY vs PBH

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Prestige Consumer Healthcare Inc.'s SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Prestige Consumer Healthcare Inc.